Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 1/20 | 0.70 |
| ▸ | BCHE | P06276 | 8/20 | 0.65 |
| ▸ | ACHE | P22303 | 4/20 | 0.65 |
| ▸ | MAOB | P27338 | 3/20 | 0.65 |
| ▸ | MGLL | Q99685 | 2/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.57 |
| ▸ | KLK7 | P49862 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17346623 | 0.92 | PTGIR (0.81) | PTGIRBCHEACHEMAOBMGLL | |
| SCHEMBL17344408 | 0.89 | MGLL (0.73) | PTGIRBCHEACHEMAOBMGLL | |
| SCHEMBL6516122 | 0.86 | PTGIR (0.72) | PTGIRBCHEACHEMAOBMGLL | |
| SCHEMBL6516120 | 0.86 | PTGIR (0.72) | PTGIRBCHEACHEMAOBMGLL | |
| SCHEMBL17342576 | 0.85 | MGLL (0.54) | PTGIRBCHEACHEMAOBMGLL | |
| SCHEMBL1118700 | 0.82 | PTGIR (1.00) | PTGIRBCHEACHEMAOBTSHR | |
| SCHEMBL1118698 | 0.82 | PTGIR (1.00) | PTGIRBCHEACHEMAOBTSHR | |
| SCHEMBL4966292 | 0.82 | NPC1 (0.64) | PTGIRMGLLTSHRNPC1ALDH1A1 | |
| SCHEMBL10192097 | 0.81 | MGLL (0.63) | PTGIRBCHEACHEMAOBMGLL | |
| SCHEMBL4964970 | 0.81 | MGLL (0.63) | PTGIRBCHEACHEMAOBMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3884934-B1 | PHARMACEUTICAL COMPOSITION COMPRISING: 2-(((1R,4R)-4-(((4-CHLOROPHENYL)(PHENYL)CARBAMOYLOXY)METHYL)CYCLOHEXYL)METHOXY)ACETIC ACID | ARENA PHARM INC (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-2857015-B1 | Modulators of the prostacyclin (PG12) receptor useful for the treatment of disorders related thereto | ARENA PHARM INC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-9611279-B2 | Zinc complex | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2017-04-04 | — | — | US | disclosed |
| US-9611279-B2 | Zinc complex | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2017-04-04 | — | — | US | disclosed |
| US-20160002268-A1 | ZINC COMPLEX | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2016-01-07 | — | — | US | disclosed |
| US-20160002268-A1 | ZINC COMPLEX | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2016-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002268-A1 | ZINC COMPLEX | SLC39A11, SLC39A3, SOD1 | PTGIR 4562/4885BCHE 4314/4885ACHE 3260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.